JP2022541332A5 - - Google Patents

Info

Publication number
JP2022541332A5
JP2022541332A5 JP2022505222A JP2022505222A JP2022541332A5 JP 2022541332 A5 JP2022541332 A5 JP 2022541332A5 JP 2022505222 A JP2022505222 A JP 2022505222A JP 2022505222 A JP2022505222 A JP 2022505222A JP 2022541332 A5 JP2022541332 A5 JP 2022541332A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022505222A
Other languages
English (en)
Japanese (ja)
Other versions
JP7843226B2 (ja
JP2022541332A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/056972 external-priority patent/WO2021019389A1/en
Publication of JP2022541332A publication Critical patent/JP2022541332A/ja
Priority to JP2023204406A priority Critical patent/JP7506817B2/ja
Publication of JP2022541332A5 publication Critical patent/JP2022541332A5/ja
Priority to JP2025211395A priority patent/JP2026064989A/ja
Application granted granted Critical
Publication of JP7843226B2 publication Critical patent/JP7843226B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022505222A 2019-07-26 2020-07-23 カリクレイン関連ペプチダーゼ2抗原結合ドメインを含むタンパク質及びその使用 Active JP7843226B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023204406A JP7506817B2 (ja) 2019-07-26 2023-12-04 カリクレイン関連ペプチダーゼ2抗原結合ドメインを含むタンパク質及びその使用
JP2025211395A JP2026064989A (ja) 2019-07-26 2025-12-01 カリクレイン関連ペプチダーゼ2抗原結合ドメインを含むタンパク質及びその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962878964P 2019-07-26 2019-07-26
US62/878,964 2019-07-26
US201962910650P 2019-10-04 2019-10-04
US62/910,650 2019-10-04
US202063030445P 2020-05-27 2020-05-27
US63/030,445 2020-05-27
PCT/IB2020/056972 WO2021019389A1 (en) 2019-07-26 2020-07-23 Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2023204406A Division JP7506817B2 (ja) 2019-07-26 2023-12-04 カリクレイン関連ペプチダーゼ2抗原結合ドメインを含むタンパク質及びその使用
JP2025211395A Division JP2026064989A (ja) 2019-07-26 2025-12-01 カリクレイン関連ペプチダーゼ2抗原結合ドメインを含むタンパク質及びその使用

Publications (3)

Publication Number Publication Date
JP2022541332A JP2022541332A (ja) 2022-09-22
JP2022541332A5 true JP2022541332A5 (https=) 2024-05-20
JP7843226B2 JP7843226B2 (ja) 2026-04-09

Family

ID=71895039

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022505222A Active JP7843226B2 (ja) 2019-07-26 2020-07-23 カリクレイン関連ペプチダーゼ2抗原結合ドメインを含むタンパク質及びその使用
JP2023204406A Active JP7506817B2 (ja) 2019-07-26 2023-12-04 カリクレイン関連ペプチダーゼ2抗原結合ドメインを含むタンパク質及びその使用
JP2025211395A Pending JP2026064989A (ja) 2019-07-26 2025-12-01 カリクレイン関連ペプチダーゼ2抗原結合ドメインを含むタンパク質及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023204406A Active JP7506817B2 (ja) 2019-07-26 2023-12-04 カリクレイン関連ペプチダーゼ2抗原結合ドメインを含むタンパク質及びその使用
JP2025211395A Pending JP2026064989A (ja) 2019-07-26 2025-12-01 カリクレイン関連ペプチダーゼ2抗原結合ドメインを含むタンパク質及びその使用

Country Status (21)

Country Link
US (2) US12077585B2 (https=)
EP (1) EP4004057A1 (https=)
JP (3) JP7843226B2 (https=)
KR (1) KR20220040483A (https=)
CN (1) CN114375302B (https=)
AU (1) AU2020322222A1 (https=)
BR (1) BR112022001368A2 (https=)
CA (1) CA3147735A1 (https=)
CL (3) CL2022000142A1 (https=)
CO (1) CO2022001891A2 (https=)
CR (1) CR20220025A (https=)
DO (1) DOP2022000013A (https=)
EC (1) ECSP22015276A (https=)
IL (1) IL289897A (https=)
MX (1) MX2022001049A (https=)
PE (1) PE20220649A1 (https=)
PH (1) PH12022550195A1 (https=)
TW (1) TWI894157B (https=)
UA (1) UA129471C2 (https=)
UY (1) UY38803A (https=)
WO (1) WO2021019389A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022001368A2 (pt) 2019-07-26 2022-05-24 Janssen Biotech Inc Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
CN116249714A (zh) 2020-05-27 2023-06-09 詹森生物科技公司 包含cd3抗原结合结构域的蛋白质及其用途
EP4182353A1 (en) 2020-07-17 2023-05-24 Janssen Biotech, Inc. Anti-idiotypic antibodies against anti-klk2 antibodies
JP2024503924A (ja) * 2021-01-27 2024-01-29 ヤンセン バイオテツク,インコーポレーテツド カリクレイン関連ペプチダーゼ2抗原結合ドメインを含む免疫コンジュゲート及びその使用
BR112023016360A2 (pt) * 2021-02-16 2024-01-23 Janssen Biotech Inc Materiais e métodos para determinação aprimorada de ligante alvo
JP7714675B2 (ja) * 2021-03-24 2025-07-29 ヤンセン バイオテツク,インコーポレーテツド CD79b、CD20、及びCD3を標的とする三重特異性抗体
JP2024512135A (ja) * 2021-03-31 2024-03-18 ヤンセン バイオテツク,インコーポレーテツド 免疫エフェクター細胞再指向のための材料及び方法
US20230011134A1 (en) * 2021-05-27 2023-01-12 Janssen Biotech, Inc. Compositions and methods for the treatment of prostate cancer
US12365743B2 (en) 2022-02-23 2025-07-22 Xencor, Inc. Anti-CD28 x anti-PSMA antibodies
WO2024089551A1 (en) * 2022-10-25 2024-05-02 Janssen Biotech, Inc. Msln and cd3 binding agents and methods of use thereof
WO2025085610A1 (en) 2023-10-18 2025-04-24 Janssen Biotech, Inc. Combination treatment of prostate cancers with two bispecific antibodies
CN117187180B (zh) * 2023-11-03 2024-01-26 四川大学 一种Th17细胞及其培养方法和应用及其诱导液
WO2025226541A2 (en) 2024-04-26 2025-10-30 Janssen Biotech, Inc. Klk2xcd3 antibody and an anti-cancer agent for treating prostate cancer
WO2025250739A1 (en) * 2024-05-31 2025-12-04 Janssen Biotech, Inc. Chimeric antigen receptor with spacer domains derived from human igg
WO2026039420A1 (en) 2024-08-13 2026-02-19 Janssen Biotech, Inc. Bispecific antibody targeting hk2 and cd3 for the treatment of prostate cancer

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2261019A1 (en) 1996-07-15 1998-01-22 Mayo Foundation For Medical Education And Research Methods to detect hk2 polypeptides
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
EP1711828A2 (en) * 2004-01-28 2006-10-18 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with kallikrein 2 (klk2)
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー/エス 二重特異性抗体の生産
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク,インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
ES2984483T3 (es) 2010-03-31 2024-10-29 Ablexis Llc Ingeniería genética de ratones para la producción de anticuerpos quiméricos
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
SG11201401422VA (en) 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
WO2013061083A2 (en) 2011-10-28 2013-05-02 Fredax Ab Therapeutic agents and uses thereof
BR112014010580B1 (pt) 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
RS60499B1 (sr) 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
AU2013289883B2 (en) 2012-07-13 2018-11-01 Zymeworks Bc Inc. Bispecific asymmetric heterodimers comprising anti-CD3 constructs
PT2931030T (pt) 2012-12-14 2020-08-03 Open Monoclonal Tech Inc Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem
MX366910B (es) 2013-03-15 2019-07-30 Janssen Biotech Inc Metodos de fabricacion para controlar el contenido de lisina c-terminal, galactosa y acido sialico en proteinas recombinantes.
SMT201900338T1 (it) 2013-11-19 2019-07-11 Fredax Ab Anticopri anti-callicreina-2 umanizzato
GB2520353A (en) * 2013-11-19 2015-05-20 Fredax Ab Antibody polypeptides and uses thereof
CN107405399B (zh) * 2015-01-02 2022-02-08 武田药品工业株式会社 针对血浆激肽释放酶和因子xii的双特异性抗体
EP3865139B1 (en) 2015-02-18 2023-05-03 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
JP2018536389A (ja) * 2015-10-02 2018-12-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト メソテリンとcd3に結合する二重特異性細胞活性化抗原結合分子
WO2017087826A1 (en) 2015-11-18 2017-05-26 Memorial Sloan Kettering Cancer Center Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods
US10882918B2 (en) 2016-09-30 2021-01-05 Hoffmann-La Roche Inc. Bispecific T cell activating antigen binding molecules
JP7538601B2 (ja) * 2017-04-26 2024-08-22 ユーリカ セラピューティックス, インコーポレイテッド キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用
WO2019060695A1 (en) 2017-09-22 2019-03-28 Kite Pharma, Inc. CHIMERIC POLYPEPTIDES AND USES THEREOF
CA3101271A1 (en) 2018-05-24 2019-11-28 Janssen Biotech, Inc. Anti-cd3 antibodies and uses thereof
BR112022001368A2 (pt) 2019-07-26 2022-05-24 Janssen Biotech Inc Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
AU2020322221A1 (en) 2019-07-26 2022-03-24 Janssen Biotech, Inc. Anti-hK2 chimeric antigen receptor (CAR)
JP2024503924A (ja) 2021-01-27 2024-01-29 ヤンセン バイオテツク,インコーポレーテツド カリクレイン関連ペプチダーゼ2抗原結合ドメインを含む免疫コンジュゲート及びその使用

Similar Documents

Publication Publication Date Title
JP2021184963A5 (https=)
JP2023171775A5 (https=)
JP2022184985A5 (https=)
JP2023103258A5 (https=)
JP2023166402A5 (https=)
JP2023518821A5 (https=)
JP2023145572A5 (https=)
JP2022543046A5 (https=)
JP2022028828A5 (https=)
JP2022025124A5 (https=)
JP2022541332A5 (https=)
JP2025511899A5 (https=)
JP2023514727A5 (https=)
JP2021185136A5 (https=)
JP2022538797A5 (https=)
JP2023552816A5 (https=)
JP2021038271A5 (https=)
JP2023181322A5 (https=)
JPWO2020148954A5 (https=)
JP2024045126A5 (https=)
JP2020171301A5 (https=)
JP2022537813A5 (https=)
JP2020120660A5 (https=)
JP2023093656A5 (https=)
JP2023078173A5 (https=)